"FDA Greenlights Groundbreaking Vaccine to Combat Global Health Crisis"

The FDA has approved Ixchiq, the world's first licensed vaccine for the mosquito-borne chikungunya virus. Developed by Valneva, the single-dose vaccine aims to prevent the potentially debilitating disease that causes fever and severe joint pain. Chikungunya is considered an emerging global health threat, with millions of cases reported since 2008. The approval of Ixchiq provides a significant advancement in preventing the disease, especially for travelers to endemic regions. Valneva plans to commercialize the vaccine in the U.S. early next year.